Song CV, Ahmad Bustamam RS, Gin Gin G, Saad M, Abdul Satar NF, Ramasamy AM, Sam IC, Kong YC, Alagir Rajah HD, Chan YF, Fu JYL, Tan CS, Danaee M, Yip CH, Van Gils CH, and Bhoo-Pathy N
Introduction: There is a lack of real-world evidence on direct comparisons between COVID-19 vaccines in multiethnic low- and middle-income settings. Cancer patients have an impaired vaccine response due to the disease itself or the effects of treatment. Hence, identifying the best vaccine to use for cancer patients is important. We aimed to compare the antibody response between cancer patients and healthy individuals following COVID-19 vaccination and assess seroconversion rates, vaccine efficacy, and the impact of sex on antibody response, as well as document adverse events in cancer patients., Materials and Methods: A prospective cohort study of cancer patients and healthy individuals receiving vaccines was conducted in Malaysia. All participants were aged 18 or above at recruitment and received at least two doses of vaccine. We excluded patients who had missing serum antibody data post-first dose and post-second dose. Sociodemographic and clinical data were collected at baseline, prior to vaccination. Data on self-reported breakthrough infection was collected at six months. Multivariable linear mixed-effects regression models were used to investigate the association between the type of vaccine and serum IgG titer., Results: A total of 389 patients with solid (n=276, 71.0%) or hematologic cancers (n=113, 29.0%) were included, along with 246 healthy individuals. Most cancer patients received BNT162b2 (n=358, 92.0%), followed by AZ1222 (n=19, 4.9%) and Coronavac (n=12, 3.1%). Most healthy individuals received BNT162b2 (n=151, 61.4%), followed by Coronavac (n=95, 38.6%). Vaccination, after adjustment for confounders (pre-vaccine infection, age, ethnicity, comorbidity, timepoint, income, cancer type, and booster), with Coronavac was associated with lower log IgG titer (-3.09 U/ml, 95% confidence interval=-4.37 to -1.80, p<0.01) than that of BNT162b2 in patients with cancer and also lower log IgG titer (-2.64 U/ml, 95% confidence interval=-2.97 to -2.30, p<0.01) than that of BNT162b2 in healthy individuals. No effect modification by sex was observed. Among the cancer cohort, 76 patients (19.5%) reported breakthrough infections after vaccination, while 33 (13.4%) participants in the healthy cohort reported breakthrough infections after vaccination. Coronavac was associated with greater odds of breakthrough infection among healthy individuals (odds ratio=7.34 compared to BNT162b2, confidence interval=1.40 to 33.49, p=0.02)., Conclusion: Vaccination with BNT162b2 yields higher IgG titer than Coronavac in all groups and fewer breakthrough infections in healthy subjects. The effect of vaccination is not modified by sex., Competing Interests: Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Medical Ethics Committee of Universiti Malaya Medical Centre issued approval 2021728-10423/NMRR-21-978-60010. The study was conducted in accordance with the Declaration of Helsinki. The approval number of the ASSeSS cohort is 2021728-10423. The approval number of the iRESPOND cohort is NMRR-21-978-60010. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: Roche Malaysia and Novartis Malaysia provided unrestricted educational grants to conduct the study. Roche Diagnostics (Malaysia) Sdn Bhd provided research materials to conduct the study. The ASSeSS Working Group was supported by ASEAN Science, Technology, and Innovation FUND (ASTIF) and Temasek Foundation. Financial relationships: Carla van Gils declare(s) a grant and non-financial support from Various Institutions/ Companies. Carla van Gils (CVG) receives research grants from Bayer and Hologic outside of the submitted work. Outside her academic work as a professor of clinical epidemiology of cancer, she is director of the Dutch Cancer Society. Nirmala Bhoo-Pathy declare(s) a grant, personal fees, non-financial support and receipt of research materials, travel support from Various Institutions/ Companies. Nirmala Bhoo-Pathy (NBP) reports receiving grants from Novartis, Pharmaceutical Association of Malaysia, Pfizer, Roche, Zuellig Pharma, Takeda and City Cancer Challenge Foundation, outside of the submitted work. NBP also reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis, Pfizer, Roche and Zuellig Pharma; received support for attending meetings or travel from Novartis, Roche, Takeda and the Pharmaceutical Association of Malaysia; reports participating on a Data Safety Monitoring Board or Advisory Board with Zuellig- Pharma, Malaysia; reports leadership or a fiduciary role in other board, society, committee, or advocacy groups, paid or unpaid with the National Cancer Society Malaysia, reports receipt of research materials from Roche Diagnostics, and reports serving as an editorial board member of eCancer and the Academic Editor of the PLOS Global Health journal, all outside of the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Song et al.)